论文部分内容阅读
目的:探讨孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效、安全性及其对患儿炎症因子的影响。方法:选取2014年2月至2016年2月我院收治的106例毛细支气管炎患儿,随机分成对照组和观察组各53例。两组患儿均给予祛痰、止咳、平喘、抗感染及抗病毒等常规治疗,对照组在常规治疗基础上加用布地奈德吸入治疗,观察组在对照组治疗的基础上再加用孟鲁司特钠口服治疗,两组疗程均为7 d。治疗1个疗程后观察两组患儿的临床疗效及不良反应发生情况,同时比较两组患儿的咳嗽持续时间、肺部音持续时间、喘憋持续时间、住院时间,以及血清嗜酸粒细胞阳离子蛋白(ECP)、白细胞介素-4(IL-4)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平的改善情况。结果:观察组治疗总有效率为92.5%,高于对照组的75.5%,差异有统计学意义(P<0.05);观察组患儿咳嗽持续时间、肺部音持续时间、喘憋持续时间及住院时间均短于对照组,差异有统计学意义(P<0.01);治疗后两组患儿血清ECP、IL-4、IL-8及TNF-α水平均改善,且观察组优于对照组,差异有统计学意义(P<0.05);治疗期间两组患儿均无明显不良反应发生。结论:孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效显著,能显著改善患儿血清ECP、IL-4、IL-8及TNF-α水平,具有较高的安全性,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of montelukast combined with budesonide in the treatment of pediatric bronchiolitis and its effect on the inflammatory factors in children. Methods: From February 2014 to February 2016, 106 children with bronchiolitis admitted to our hospital were randomly divided into control group and observation group of 53 cases. The two groups of children were given expectorant, cough, asthma, anti-infective and anti-virus and other conventional treatment, the control group on the basis of conventional treatment with budesonide inhalation therapy, the observation group in the control group based on the treatment plus Montelukast oral treatment, two courses of treatment were 7 d. After treatment for 1 course of treatment, the clinical efficacy and adverse reactions of the two groups were observed. The duration of cough, the duration of lung tone, duration of wheezing, hospital stay and serum eosinophils (ECP), interleukin-4 (IL-4), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) Results: The total effective rate of observation group was 92.5%, higher than 75.5% of the control group, the difference was statistically significant (P <0.05); duration of cough in children in the observation group, lung tone duration, duration of wheezing (P <0.01). After treatment, the levels of serum ECP, IL-4, IL-8 and TNF-α in both groups were improved, and the observation group was better than the control group Group, the difference was statistically significant (P <0.05); no adverse reactions occurred in both groups during treatment. Conclusion: The clinical efficacy of montelukast combined with budesonide in the treatment of children with bronchiolitis is significant, can significantly improve children with serum levels of ECP, IL-4, IL-8 and TNF-α, with high safety, it is worth Clinical application.